NASDAQ / LIVE COMPANY INTELLIGENCE

Mangoceuticals, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERMGRX
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / MGRX COVERAGE

What’s moving Mangoceuticals, Inc. now

Current reporting with the operating signal separated from the noise.

01
Mangoceuticals, Inc.: Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology

Mangoceuticals, Inc.: Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology

The story matters when it changes Mangoceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: deployment, backlog, capacity and segment margin.
02
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

The story matters when it changes Mangoceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

The story matters when it changes Mangoceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

The development tests whether Mangoceuticals, Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
05
Mangoceuticals, Inc. Provides Update to Shareholders on Q3 Achievements and Guidance on Year End and Near-Term Initiatives

Mangoceuticals, Inc. Provides Update to Shareholders on Q3 Achievements and Guidance on Year End and Near-Term Initiatives

Investors are testing whether Mangoceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
Mangoceuticals, Inc. Now Featured on Webull Corporate Communications Service Platform

Mangoceuticals, Inc. Now Featured on Webull Corporate Communications Service Platform

The story matters when it changes Mangoceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest MGRX filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-19 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-14 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-04-01 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-30 · Period 2026-07-28SEC ↗8-KMaterial company eventFiled 2026-07-02 · Period 2026-06-29SEC ↗8-KMaterial company eventFiled 2026-03-17 · Period 2026-03-16SEC ↗DEF 14AProxy and shareholder meetingFiled 2025-02-18 · Period 2025-02-18SEC ↗425Official SEC filingFiled 2026-07-30SEC ↗
EARNINGS / QUARTERLY TRACKER

Mangoceuticals, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.